American Health Intel
Tools

Payer earnings calendar

Who reports when, and the single number that will move the story.

Already reported

  1. MedtronicMDT

    Raised fiscal 2027 non-GAAP diluted EPS guidance of $5.94 to $6.00

  2. Definitive HealthcareDH

    Turbo AI platform adoption and customer retention as revenue stabilizers

  3. RadNet Inc.RDNT

    AI-specific revenue up 136% year over year; AI annual recurring revenue nearly doubled to $105.5 million

  4. American Healthcare REITAHR

    $1.4 billion in new investments completed since the start of 2026, with more than $800 million more in the pipeline; raised FY2026 guidance to $2.15 to $2.19 normalized FFO per diluted share

  5. AMN Healthcare ServicesAMN

    Q3 2026 revenue guidance of 640 to 655 million dollars

  6. GoodRx, Inc.GDRX

    Pharma Direct revenue growth rate versus legacy prescription transaction decline

  7. Doximity, Inc.DOCS

    AI Search revenue recognition in coming quarters

  8. Privia HealthPRVA

    implemented providers, 5,644, and value-based care attributed lives, 1.647 million

  9. Oscar Health

    implied second-half operating loss of roughly 393 million to 593 million dollars

  10. Clover HealthCLOV

    Medicare Advantage membership, 157,309, up 48 percent year over year

  11. CVS HealthCVS

    Adjusted EPS rose 42.5 percent to $2.58 and revenue climbed 7.3 percent to $106.1 billion; full year adjusted profit guidance raised to $7.90 to $8.10 per share, but shares fell about 9 percent

  12. agilon healthAGL

    Full-year 2026 revenue guidance raised to 5.775 to 5.86 billion dollars

  13. Eli LillyLLY

    Full year 2026 revenue guidance raised to 85 to 87 billion dollars, the second raise this year

  14. CVS HealthCVS

    Full year 2026 adjusted EPS guidance raised to 7.90 to 8.10 dollars

  15. DaVitaDVA

    Integrated Kidney Care adjusted operating income $40 million vs $19 million Q1 loss; 64,900 value-based patients, $5.8 billion annualized medical spend under management

  16. Hinge HealthHNGE

    Full year 2026 revenue guidance raised to $856-860 million

  17. Novo NordiskNVO

    Oral Wegovy pill sales of 3.22 billion Danish kroner versus about 3.27 billion kroner expected

  18. PfizerPFE

    Full year 2026 revenue guidance raised to $60.5 billion to $62.5 billion

  19. Healthcare Realty Trust

    Full-year 2026 same-store cash NOI growth guidance raised to a range of 4.25% to 5%, alongside a redevelopment pipeline expanding to roughly 30 assets by year end

  20. Alignment Healthcare

    Adjusted medical benefit ratio improved to 86.3%, the lowest since the company went public, while full-year 2026 membership guidance was raised to 298,000-301,000

  21. Regeneron PharmaceuticalsREGN

    Whether the Q3 step-up in Sanofi collaboration profit, now that the Development Balance is fully repaid, shows up in guidance.

  22. Bristol Myers SquibbBMY

    Growth Portfolio revenue (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag), up 15% to 7.6 billion dollars and now nearly 60% of total revenue

  23. The Cigna GroupCI

    Medical care ratio rose to 84.5 percent

  24. Ventas, Inc.VTR

    Full year 2026 senior housing investment target raised to more than 4.5 billion dollars, up from 3 billion dollars

  25. Humana Inc.HUM

    Benefit ratio rose to 91.2% from 89.9%; GAAP EPS guidance floor cut to at least $6.52 from at least $8.36

  26. Boston Scientific Corporation

    $5.442B net sales (+7.5%); FY adjusted EPS guidance $3.28-$3.32 vs $3.36 consensus

  27. Grifols, S.A.

    29 US plasma donor center closures amid a July 1, 2026 reorganization separating US and global plasma operations

  28. Centene CorporationCNC

    Marketplace enrollment under the Ambetter brand, which fell to 3.5 million from 5.8 million a year ago

  29. Universal Health ServicesUHS

    Full year adjusted diluted EPS guidance of 22.28 to 23.65 dollars

  30. Gentherm IncorporatedTHRM

    400 million dollar stock buyback authorization and the roughly 1 billion dollar Modine Performance Technologies combination closing

  31. Tenet HealthcareTHC

    Adjusted EPS 6.12 dollars vs 4.26 dollar consensus; FY2026 EPS guidance raised to 20.30-21.69 dollars

  32. Quest DiagnosticsDGX

    Adjusted EPS growth of 19.1% to 3.12 dollars; FY2026 revenue guidance raised to 11.95-12.05 billion dollars

  33. HCA HealthcareHCA

    ~400 million dollar ACA coverage-loss hit nearly offset by ~400 million dollar Florida Medicaid Supplemental Payment Program benefit

  34. Molina HealthcareMOH

    Full-year 2026 revenue guidance held near 42 billion dollars, about 2.28 billion dollars below analyst expectations of roughly 44.28 billion dollars

  35. Community Health SystemsCYH

    Full-year 2026 guidance of a diluted loss per share of 1.10 to 1.25 dollars

  36. Intuitive SurgicalISRG

    US da Vinci procedure growth rate against full-year guidance of 13.5 to 15.5 percent

  37. UnitedHealth GroupUNH

    Medical care ratio fell to 86.7% of premiums from 89.4% a year earlier; full-year adjusted EPS guidance raised to $19.50-$20.00

  38. Johnson & JohnsonJNJ

    J&J raised full-year 2026 guidance to about $101.1 billion in sales, on pace to top $100 billion for the first time; Abbott also beat estimates, raising full-year adjusted EPS guidance to $5.45-$5.60

  39. HCA Healthcare

    Full-year 2026 ACA exchange hit now estimated at $1.0 billion to $1.2 billion, up from a prior $600 million to $900 million estimate

  40. Elevance Health

    Medical loss ratio rose 80 basis points to 89.7%; medical membership fell to about 44.9 million, down 469,000 from the prior quarter